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Purpose: Seeding prosthetic arterial grafts with genetically modified endothelial cells (ECs) 
has the potential to substantially improve graft fimction. However, preliminary applica- 
tions suggest that grafts seeded with retrovirally transduced ECs yield a significantly lower 
percent surface coverage than those seeded with nontransduced ECs. The objective ofthis 
study was to test the hypothesis that canine ECs transduced with the human tissue 
plasminogen activator (tPA) gene would have a lower rate of  adherence to pretreated 
expanded polytetrafluoroethylene (ePTFE) both in vitro and in vivo and that they would 
proliferate at a slower rate on pretreated ePTFE in vitro. 
Methods: Early passage ECs derived from canine external jugular vein were transduced 
with the retroviral MFG vector containing the gene for human tPA. ECs exposed to media 
alone served as controls. Iodine 125-1abeled ECs were seeded in vitro onto ePTFE graft 
segments pretreated with canine whole blood, fibronectin (50 ~tg/ml), or media alone, and 
the percent of  ECs adherent at 1 hour were determined (n = 3). Additional tPA- 
transduced and -nontransduced ECs were grown for 10 days on either fibronectin (50 
~g/ml)-pretreated ePTFE wafers or tissue culture plastic pretreated with gelatin (1%) or 
fibronectin (50 Cg/ml), and the EC proliferation rates were determined (n = 3). 
Furthermore, 12~I-labeled ECs were seeded onto fibronectin (50 ~tg/ml)-pretreated 
ePTFE graft segments implanted as carotid and femoral artery interposition grafts 
(n = 3). The grafts were harvested after 1 hour, and the percent of  ECs adherent was 
determined. 
Results: Human tPA was detected by immunohistochemical staining in 61% -+ 5% of the 
transduced ECs and was expressed at 35.4 -+ 12.9 ng/hr/lO 6 cells. Fibronectin and whole 
blood pretreatment of  the ePTFE grafts led to greater EC adherence in vitro than did 
media alone (90.9% + 5.3% vs 77.8% --- 5.8% vs 4.7% -+ 1.1%,p < 0.05). No signifi- 
cant difference in the rates of  adherence or proliferation was seen in vitro between the 
transduced and nontransduced ECs. No significant difference in proliferation was found 
for the transduced ECs on the three matrices tested in vitro. In contrast, adherence of the 
transduced ECs in vivo was significantly lower than that of  nontransduced ECs 
(64.7% + 2.1% vs 73.7% - 4.1%,p <0.05) 1 hour after implantation. 
Conclusions: Lower rates of  surface ndothelialization bygenetically modified ECs in vivo 
do not appear to be due to an impaired capacity to initially adhere or proliferate on the 
synthetic graft but may result from decreased adherence after exposure to in vivo 
hemodynamic forces. (J VAsc SURG 1995;22:795-803.) 
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Use of small-caliber prosthetic bypass grafts has 
been limited by poor long-term patency rates. 
Endothelial cell (EC) seeding of these grafts has been 
proposed as a method to decrease their inherent 
thrombogenicity. Although animal studies have 
documented improved graft patency rates with this 
technique, 1,2 human applications have been inconsis- 
tent and have been largely abandoned.as 
Recent advances in gene therapy have made it 
possible to seed prosthetic grafts with genetically 
modified ECs, thus offering considerable potential to 
reduce their inherent thrombogenicity b  delivery of 
a desired gene product such as tissue plasminogen 
activator (fr'A). The first application of thi~s technol- 
ogy was reported by Wilson et al., 6 who seeded 
Dacron grafts with retrovirally transduced ECs con- 
taining the lacZ marker gene and subsequently 
implanted them into the carotid artery position of 
dogs. Genetically modified ECs were identified on 
the lumen of the grafts 5 weeks after implantation. 
Podrazik et al. 7 seeded ECs retrovirally transduced 
with the lacZ gene onto expanded polytetrafluoro- 
ethylene (ePTFE) conduits that were implanted as 
thoracoabdominal grafts in dogs. A significantly 
lower percent surface ndothelialization was detected 
at 6 weeks on grafts seeded with the transduced ECs 
compared with those seeded with the nontransduced, 
control ECs. Similarly, Sackman et al. 8 seeded ECs 
retrovirally transduced with a neomycin resistance 
gene onto ePTFE grafts implanted in dogs. Serial 
biopsies ofgraft surfaces revealed patchy EC coverage 
in the control (nontransduced) group at 18 weeks 
after implantation, whereas transduced ECs were 
detected only up to 3 weeks after implantation. 
The studies of Podrazik et al. 7 and Sackman et al.8 
suggest that retrovirally transduced ECs seeded onto 
prosthetic grafts behave differently than nontrans- 
duced ECs after implantation of the grafts in vivo. 
Indeed, Brothers et al.9 reported that canine ECs 
transduced with BAG retroviral vector containing the 
lacZ and Tn5 genes had a significantly ower prolif- 
eration rate during log phase growth in tissue culture. 
In contrast, Jaklitsch et al. t0 reported a comprehen- 
sive series of in vitro experiments examining cell 
attachment, proliferation, and migration of retroviral 
tPA-transduced bovine ECs. In these studies trans- 
duction led to a small decrease in the horizontal 
migration rate, but no differences in attachment or
proliferation were observed. 
This investigation was designed to characterize 
the function of tPA-transduced ECs on the surface of 
prosthetic grafts in preparation for a longer term in 
vivo study. Three specific hypotheses were teste& 1) 
canine jugular vein ECs retrovirally transduced to 
express the human tPA gene will exhibit a decreased 
initial adherence topretreated PTFE grafts in vitro; 
2) allogenic canine jugular vein ECs retrovirally 
transduced to express the human tPA gene and 
seeded onto pretreated small caliber ePTFE grafts 
will exhibit a lower adherence rate 1 hour after 
implantation in vivo; 3) canine jugular vein ECs 
retrovirally transduced with the human tPA gene will 
proliferate at a slower rate than nontransduced ECs 
on the surfaces of pretreated ePTFE grafts in vitro. 
MATERIAL AND METHODS 
EC derivation and cultivation. ECs were har- 
vested from excised external jugular veins of three 
adult male mongrel dogs with standard technique, n 
The ECs were then resuspended in media (M199; 
Gibco Laboratories, Grand Island, N.Y.) supple- 
mented with 20% bovine calf serum (Hyclone 
Laboratories, Logan, Utah), EC growth supplement 
(25 ~g/ml, Collaborative Research, Inc., Bedford, 
Mass.), heparin (15 U/tal, Sigma Chemical Co., St. 
Louis, Mo.), glutarnine (2 mmol/L, Gibco Labora- 
tories), and penicillin/streptomycin (100 U/tal/100 
~g/ml, Gibco Laboratories) and plated onto gelatin 
(1%, Sigma Chemical Co.)-coated 25 cm 2 tissue 
culture flasks (T25; Costar Corp., Cambridge, 
Mass.). The media was changed every 2 days until the 
ECs reached confluence. The concentration of the 
bovine calf serum in the media was decreased to 5% 
on the second day after harvest, with all other 
components of the media remaining the same (com- 
plete EC media). The confluent ECs were split 1:10 
every 7 days. EC suspensions were obtained for 
both cell splits and cell counts with 0.1% 
trypsin/ethylenediamine tetraacetic acid (Gibco 
Laboratories), and EC counts were performed with a 
Coulter counter (Coulter Electronics, Inc., Hialeah, 
Fla.). The derived cells were confirmed to be more 
than 99% ECs by morphologic study and by 
demonstration of the ligand Dil-Ac-low-density 
lipoprotein (Biomedical Technologies, Inc., Stough- 
ton, Mass.) with fluorescent microscopy. 
Retroviral EC transduction. Optimal condi- 
tions for retroviral gene transfer with the MFG-hu- 
man tPA vector have been previously reported from 
our laboratory. 12The MFG-tPA vector was pro- 
duced by the q~CRIP producer line maintained 
in Dulbecco's modified Eagle medium-high glucose 
(Gibco Laboratories) supplemented with 10% fe- 
tal calf serum (Hyclone Laboratories) and peni- 
cillin/streptomycin (100 U/ml/100 ~g/ml). Vector 
titers were determined by exposing subconfluent 
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Table I. Human tPA production (ng/106/hr) 
Day Gelatin Fibronectin Fibronectin/ePTFE 
4 22.0 -+ 6.5 25.7 _+ 7.9 33.8 + 2.6 
10 27.2 + 14.9 48.0 _+ 7.9 « 28.6 + 17.7 
«Significantly greater quantity of human tPA was produced on day 10 by the transduced ECs on fibronectin. Quantity of human tPA 
produced on days 4 and 10 by the transduced ECs in the proliferation study (n = 3) on the different matrix preparations (paired t test~ 
p < 0.05). No significant difference was noted among the surface matrices for any given day (ANOVA/Scheffe's, p _< 0.05). 
plates of NIH 3T3 cells to serial dilutions of the 
vector stocks and performing immunohistochemical 
staining of these cells to identify clones expressing the 
human tPA. The vector supernatant was found to 
contain 0.5 to 1.5 x 106 colony forming units/ml 
and was found to be negative for the presence of any 
helper virus) 3 The ECs were plated on T25 flasks at 
a density of 5 x 103 cells/cm 2. Approximately 72 
hours after plating during the log phase of growth, 
the ECs were exposed to the MFG-tPA vector in the 
presence of polybrene (8 ~tg/ml, Sigma Chemical 
Co.). Control cells were obtained by exposing the 
ECs to media alone (Dulbecco's modified Eagle 
medium-high glucose, 10% fetal calf serum, 
penicillin/streptomycin) in the presence of the poly- 
brene. Two 12-hour exposures to either the vector or 
media were performed on subsequent days. ECs were 
used for the various protocols approximately 24to 48 
hours later. 
tPA antigen assays. The quantity of human tPA 
secreted by transduced ECs was determined imme- 
diately before use of the cells in the various protocols. 
An aliquot of the media was collected from the T25 
flasks, and the levels of the human tPA were measured 
with ä modified enzyme-linked immunosorbent assay 
(ELISA) (Imubind-5; American Diagnostica, Inc., 
Greenwich, Conn.). The tPA secretion rate was 
expressed as nanograms/hour/lO 6 cells. 
Immunohistochemical staining. The trans- 
duced and nontransduced control ECs were plated 
onto gelatin-pretreated 12-weU tissue culture plates 
(T-12; Costar Corp.) at the time of the graft seeding 
for the adherence studies and at the time ofplating for 
the proliferation study. The ECs were allowed to 
adhere and spread for approximately 2 hours. They 
were then washed with phosphate-buffered saline 
solution (Gibco Laboratories), fixed in 3.7% form- 
aldehyde (Eastman Kodak Co., Rochester, N.Y.) for 
30 minutes, and permeabilized with 100% methanol 
(Fisher Scientific, Pittsburgh, Pa.) for 2 minutes. The 
cells were then sequentially incubated with 3% 
normal nonimmune rabbit serum (Vector Laborato- 
ries, Inc., Burlingame, Calif.) for 30 minutes and 
goat anti-human uteri tPA immunoglobulin G (50 
pùg/ml, American Diagnostica Inc.) for 2 hours. 
Subsequently, the ECs were exposed to biotinylated 
rabbit anti-goat IgG (5 Ixg/ml, Vector Laboratories, 
Inc.) for 30 minutes and incubated for 30 minutes 
with an avidin-biotin-horseradish-peroxidase com- 
plex (Vectastain ABC; Vector Laboratories, Inc.). 
Finally, the ECs were exposed to the peroxidase 
substrate 3-amino-9-ethylcarbazole (AEC; Vector 
Laboratories, Inc.) for 2 to 10 minutes. The stained 
EC monolayers were examined by a blinded observer, 
and the percentage of ECs staining positive for 
human tPA were determined. 
EC labeling with 12si. Confluent T-25 plates of 
ECs were incubated with 2 ml diluent C contain- 
ing 6 ~Ci of 12»I-PKH-95 (Zynaxis Cell Science, 
Malvern, Pa.) for 1.5 minutes. 14 Bovine plasma- 
derived serum was then added for i minute. The 
plates were then washed five times with complete 
EC medium containing 20% bovine plasma-derived 
serum and refed with complete EC media con- 
taining 5% bovine plasma. 125I-PKH-95 is a lipo- 
phjlic compound that irreversibly binds to the EC 
membrane and does not leak into the surrounding 
tissues not cells. 1517 The radioacuvity of the graft 
surfaces in the adherence studies was determined 
with a gamma counter (Packard Instrument Co., 
Meriden, Conn.). 
In vitro EC adhesion. Early passage canine ECs 
(passage 2 to 4) from three separate animals (n = 3) 
were either transduced during log phase growth with 
the retroviral MFG-tPA vector or exposed to cell 
media alone. The ECs were labeled at confluence 
with 12~I and then seeded at a density of 104 cells/cm 2 
for 60 minutes on 5 cm segments of 8 mm internal 
diameter, thin-walled ePTFE grafts. Graft surfaces 
were pretreated for 60 minutes immediately before 
EC seeding by exposure to one ofthree preparations: 
human fibronectin (50 ~g/ml, Sigma Chemical Co.), 
canine whole blood, or cell media (M-199). The 
percent of adherent ECs were determined by the ratio 
of the radioactive counts on the graft surface to that 
of the seeding media. All experiments were per- 
formed in duplicate. EC expression of the human tPA 
gene was confirmed before graft seeding by ELISA 
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for the ff'A in the media and by immunohistochemi- 
cal staining. 
EC proliferation. Early passage canine ECs 
(passage 2 to 4) from three separate animals (n = 3) 
were transduced during log phase growth with the 
retroviral MFG-tPA vector or exposed to cell media 
alone. At confluence, the ECs were passaged and 
plated onto either pretreated tissue culture polysty- 
rene or pretreated thick-walled ePTFE wafers. The 
polystyrene was pretreated with either human fi- 
bronectin (50 Ixg/ml) or gelatin (1%) for 60 minutes. 
The ePTFE was pretreated with human fibronectin 
(50 I~g/ml) for 60 minutes. Cell counts were 
determined 1, 4, 7, and 10 days after plating. Cell 
suspensions were prepared by enzymatically remov- 
ing the ECs attached to the tissue culture plastic or 
ePTFE with 0.1% trypsin/ethylenediaminc tetraace- 
tic acid, and counts were determined by use of a 
Coulter counter. Complete EC removal was con- 
firmed by microscopic evaluation of the tissue culture 
plastic or ePTFE. All experiments were performed in
triplicate. EC gene expression of human tPA was 
confirmed before plating by an ELISA assay of the 
media and by immunohistochemical st ining. 
In vivo EC adhesion. Early passage canine ECs 
(passage 2 to 4) from three different animals (n = 3) 
were transduced during log phase growth with the 
retroviral MFG-tPA vector or exposed to cell media 
alone. ECs were labeled at confluence with 12sI and 
then seeded at a density of 104 cells/cm 2 for 60 
minutes onto 8 cm segments of 4 mm internal 
diameter thin-walled ePTFE grafts. Graft surfaces 
were pretreated for 60 minutes immediately before 
EC seeding by exposure to human fibronectin (50 
~g/ml). Transduced and nontransduced EC-seeded 
graft segments, 6 cm in length, were then implanted 
end-to-end in either the carotid or femoral artery 
positions of anesthetized (17 mg/kg Brevital, Eli Lilly 
Co., Indianapolis, Ind.) dogs in random order by use 
of a standard vascular technique. A total of four grafts 
were implanted in each animal with one transduced 
and one nontransduced EC-seeded graft implanted in
each carotid and femoral artery position. Before 
implantation the animals were anticoagulated with 
heparin (150 ~g/kg). After implantation, blood flow 
was restored, and the graft segments were perfused 
for 60 minutes, at which time they were harvested en 
toto by incision of the suture line and were genfly 
washed to remove any nonadherent cells. Graft 
radioactivity was then determined. The percent of 
adherent ECs was determined by the ratio of the 
counts of the implanted graft surface to that of the 
nonimplanted graft segments that were seeded, 
incubated, washed, and counted in parallel. All 
experiments were performed in duplicate. EC gene 
expression for human tPA was contirmed before graft 
seeding by an ELISA assay of the media and by 
immunohistochemical st ining. 
Statistical analysis. The percent of transduced 
and nontransduced a herent ECs on graft surfaces 
both in vitro and in vivo were compared by use of a 
one-tailed, paired t test, with a p value _<0.05 
accepted as significant. The in vitro adherence of 
transduced ECs for the three graft pretreatments was 
compared by use of analysis of variance (ANOVA), 
and Scheffe's confidence intervals were used to 
determine the differences with a p value _<0.05 
accepted as significant. The best fit exponential curve 
was determined for the profiferation experiment and 
the doubling time calculated. The doubling times of 
both the transduced and nontransduced ECs were 
expressed asa percentage ofthe doubling time of the 
nontransduced ECs grown on gelatin in an attempt 
to decrease the variability between the individual, 
primary EC cultures. These normalized values for the 
transduced and nontransduced ECs were then com- 
pared by use of a one-tailed, paired t test, with a p 
value -< 0.05 accepted as significant. The normalized 
values for the transduced ECs on the three surfaces 
were compared by use of ANOVA, and Scheffe's 
confidence intervals were used to determine the 
significant differences with ap value -< 0.05 accepted 
as significant. The quantity of human tPA secreted by 
the transduced ECs in the proliferation protocol was 
compared between day 4 and day 10 by use of a 
two-tailed, paired t test, with a p value _<0.05 
accepted as significant. It was compared among 
surface pretreatments for a given day by use of 
ANOVA, and Scheffe's confidence intervals were 
used to determine the significant differences with ap 
value -<0.05 accepted as significant. All statisucal 
analyses were performed on a Macintosh Centris 610 
(Apple Computer Corp., Cupertino, Calif.) com- 
puter with the Statview 512 software (Brain Power 
Inc., Calabasas, Calif.). 
Experimental pproval. All experimental pro- 
cedures conformed to the guidelines established by 
the American Physiological Society and the National 
Institute of Health (Guide for the Care and Use of 
Laboratory Animals, NIH Publication No. 85-23, 
1985) and was approved by the University of 
Michigan Committee on Use and Care of Animals. 
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Fig. 1. EC monolayer after immunohistochemical staining for human tPA. (Original 
magnification x 200.) Cyxoplasm of ECs expressing human tPA stains red. Percentage of ECs 
expressing human tPA was determined by blinded observer. 
The animals used for the in vivo adherence protocol 
were killed at the completion of the experiment with 
pentobarbital (Uthol; Butler Co., Columbus, Ohio). 
RESULTS 
High level expression of human tPA was detected 
in all ECs exposed to the MFG-tPA retroviral vector 
(35.4 + 12.9 ng/hr/106 cells). A high transduction 
efficiency was documented with human tPA detected 
by immtmohistochemical staining in 61% + 5% 
(mean + SEM) of the ECs (Fig. 1). 
Pretreatment of the graft surfaces with either 
fibronectin or blood led to significantly greater 
adherence for the transduced ECs relative to pretreat- 
ment with media alone (ANOVA/Scheffe's) (Fig. 
2,A). No significant difference in adherence was 
detected between the transduced and nontransduced 
ECs, respectively, on the ePTFE graft segments 
treated with either fibronectin (99.8% + 5.1% 
vs 90.9% + 5.3%), blood (86.8% + 3.2% vs 
77.8% + 5.8%) or media (4.8% + 1.1% vs 
4.7% + 0.8%) (paired t test, n = 3) (Fig. 2,B). 
No significant differences were noted among 
the normalized percent doubling times between 
the transduced and nontransduced ECs, respec- 
tively, on either the gelatin (114.4% + 25.6% vs 
100%), fibronectin (112.7% + 14.2% vs 101% + 
28.4%), or ePTFE/fibronectin (166.5% + 21.7% vs 
123.6% + 15.6%) surfaces (paired t test, n = 3), 
although atrend toward significance was noted in the 
latter group (p = 0.15) (Fig. 3). No significant dif- 
ference was found for the doubling times of the 
transduced ECs on the three surface matrices 
(ANOVA/Scheffe's). High expression of the human 
tPA gene was detected by the transduced ECs on days 
4 and 10 (Table I). A significantly greater quanräty of 
human tPA was secreted by ECs seeded on fibronec- 
tin at 10 days (48.0 + 7.9 vs 25.7 + 7.9 ng/ml/106 
ceils/hr) (paired t test). There was no significant dif- 
ference in the quantity of the human tPA among the 
surfaces for a given time point (ANOVA/Scheffe's). 
In the in vivo experiment, both the transduced 
and nontransduced ECs adhered weil to the 
fibronectin-pretreated ePTFE surface 1 hour after 
implantanon and exposure to normal arterial perfu- 
sion (64% + 2.1% vs 73.7% + 4.1%), although 
transduced ECs adhered at a significantly ower rate 
(paired t test, n = 3) (Fig. 4). 
DISCUSSION 
This invesnga6on provides everal new contribu- 
tions to our understanding of gene transfer to 
vascular cells. Retroviral transduction with the hu- 
man tPA gene did not decrease the in vitro adherence 
of the ECs seeded onto pretreated ePTFE grafts. 
Human fibronectin and canine whole blood provided 
the best pretreatments for in vitro graft EC seedingl 
The proliferative rate of the transduced ECs was not 
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Fig. 2. In vitro adherence smdy. (A) Percent adherence of
tPA-transduced ECs alone to ePTFE is shown for three 
surface pretreatments. Adherence of transduced ECs on 
ePTFE surfaces pretreated with fibronectin or blood were 
significantly greater than those pretreated with media lone 
(ANOVA/Scheffe's,p < 0.05). (B) Percent adherence of 
both tPA-transduced and -nontransduced ECs to ePTFE 
surfaces for three surface pretreatments (n = 3). No 
significant difference in adherence was seen between 
transduced and nontransduced ECs (paired t test, 
p _< 0.o5). 
different from that of nontransduced ECs on gelatin, 
fibronectin, or fibronectin/ePTFE surfaces. Further- 
more, no significant difference was seen in the 
proliferation rate of transduced ECs on the three 
matrices, and they continued to express high levels of 
human tPA throughout the duration of the experi- 
ment. Surprisingly, the adherence of tPA-transduced 
ECs on fibronectin-pretreated ePTFE grafts in vivo 
was significanüy less than for the nontransduced ECs 
at 1 hour after implantation. 
The mechanism responsible for the decreased 
adherence of the tPA transduced ECs in vivo is not 
known. Retroviral gene transfer and expression may 
lead to alterations in EC adhesion molecules either 
quantitatively or qualitatively and thus affect their 
ability to adapt to the shear stress of blood flow. 
Addi6onally, the human tPA expressed may exert a 
proteolytic effect on the underlying cellular matrix 
and lead to a sloughing ofECs from the graft surface. 
TPA acts by cleaving plasminogen to plasmin, and 
plasmin is known to induce proteolysis of matrix 
proteins uch as laminin and fibronectin. ~8 However, 
this explanation was partially refuted by Jaklitsch et 
al., 1° who reported no decrease in adherence for 
tPA-transduced bovine ECs cultured on gelatin- 
treated tissue culture plates. 
Transduced allogenic ECs seeded on the graft 
surfaces in this study could conceivably have induced 
an inflammatory or immune response. However, the 
significance of this is uncertain. Only hyperacute 
rejection caused by preformed circulating antibodies 
could explain rejection occurring within the 1-hour 
time course of the experiment. Furthermore, non- 
transduced allogenic ECs were included as controls. 
Yang et al) 9 recently reported that adenoviral vec- 
tor-mediated gene transfer and expression is limited 
by low level vital genome expression, with the 
resultant viral-specific eU immunity leading to cell 
destruction. It is possible that retroviral transduction 
could lead to a similar response. Again, this type of 
response would not likely be contributory within the 
1-hour time course of this study. Finally, the 
underlying biology of the retrovirus i such that it can 
exist as a stable entity within the host genome. 
Long-term gene expression has been reported within 
the vasculature by Lynch et al. 2° after seeding 
transduced smooth muscle cells onto injured rat 
carotid arteries. It is likely, however, that the biologic 
response of both the host and the transplanted ECs 
to seeding on a prosthetic graft differs from that of 
either ECs or smooth muscle cells seeded onto an 
injured or endarterectomized vessel. Krause et al. 21 
have shown that ePTFE causes the activation of 
phagocytic leukocytes after adherence and is associ- 
ated with an increased release of toxic oxygen 
intermediates. AdditionaUy, Margiotta et al. 22 have 
shown that pretreating Dacron grafts with either 
fibronectin or whole blood increased the expression 
of intracellular adhesion molecute (ICAM-1) on 
seeded human saphenous vein ECs in vivo. ICAM-1 
is a glycoprotein expressed on ECs that acts as a 
ligand for the lymphocyte-function-associated anti- 
gen that is responsible for cell-to-cell interaction in 
both the immune and inflammatory esponses. It is 
possible that retroviral transduction may angment 
neutrophil-mediated EC destruction after seeding on 
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Fig. 3. Proliferation smdy. Normalized percent doubling times (doubling time expressed as 
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times between transduccd and nontransduced ECs on any of prepared surfaces (paired t test, 
]2 _< 0.05). Additionally, no significant difference in normalized pereent doubling times for tPA 
transduced ECs was seen on three matrices (ANOVA/Scheffe's, p _< 0.05) 
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-nontransduced ECs to fibronectin-pretreated ePTFE surfaces i shown (n = 3) documenting 
that tPA transduced ECs had significantly ower adherence (paired t test, p _< 0.05). 
the prosthetic surface. Last, the human tPA gene 
product itselfmay induce an immune response in the 
dog, although many early efficacy studies of human 
tPA were performed without difficuhy in the 
dog.  23-2s 
The two in vitro components ofthis investigation 
provide both insight into the seeding of tPA- 
transduced ECs and optimism for application of this 
technique. Both whole blood and fibronectin pre- 
treatment of the ePTFE graft surfaces resulted in 
greater than 78% EC adherence. Thus either prepa- 
ration may be appropriate for in vivo applications. 
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The ePTFE graft surfaces were pretreated with 
fibronectin for the in vivo study because of the 
slightly greater adherence observed in our in vitro 
study, as weil as reported by others.26,27 The ability of 
the transduced ECs to proliferate on the various 
surfaces at comparable rates to nontransduced ECs 
while continuing to secrete tPA was likewise encour- 
aging and concurs with the report of Jalditsch et a1.1° 
Nevertheless, proliferation of ECs on fibronectin- 
pretreated ePTFE has not been a universal observa- 
tion. 28 Clearly, the interpretation of the in vitro 
proliferation studies are limited because the growth 
conditions in vivo likely differ. Additionally, the 
surface of the grafts are modified in vivo by the 
&position of fibrin and thrombus. Whole blood 
pretreatment of the ePTFE was not included in the 
proliferation study because of our initial in vitro 
adherence data and because of the practical reason 
that the blood and thrombus did not remain adherent 
to the ePTFE surfaces in tissue culture. 
The MFG-tPA retroviral vector was chosen be- 
cause of its efficacy and potential for human trials. 
Human tPA was expressed by 61.5% of the ECs 
exposed to the vector without he need for selection. 
Although selection, such as with the neomycin 
resistance gene, essentially assures a cell population 
of approximately 100% transduced cells, it adds to 
the complexity of the experiment and introduces 
potential for infection and contamination, thus 
limiting human applications of the technology. 
Furthermore, it has been suggested that the pres- 
ence of the neomycin resistance gene and gene 
product may potentially inhibit proliferation. 7,9 
However, it must be emphasized that our results 
are based on a cell population in which 61.5% of 
the cells exposed to the MFG-tPA vector expressed 
the human gene product. It is conceivable and 
possible that a cell population in which 100% of 
the cells expressed the human tI'A would behave 
differently, but it is most likely that they would 
further emphasize the observed ifference. 
The experiment was designed such that nontrans- 
duced ECs served as the controls for the tPA- 
transduced ECs. These control cells were subjected to 
a sham transduction protocol, although they were 
not exposed to the retroviral vector. This control 
allows us to conclude that the observed ecrease in 
adherence of the transduced ECs was due to the 
retroviral transduction and the human tPA gene 
expression. An appropriate additional control would 
have been ECs transduced with either the MFG 
vector containing a marker gene such as lacZ or a 
mock MFG vector containing all the necessary genes 
for viral incorporation and gene expression but 
lacking the tPA gene. Indeed, preliminary in vivo 
adherence and proliferation studies with the MFG- 
lacZ vector do not appear to be different han the 
tPA transduced and nontransduced ECs (data not 
shown). 
This investigation supports the conclusion that 
the decreased percent surface endothelialization f
prosthetic graft surfaces reported in the literamre 
after seeding of retrovirally transduced ECs cannot be 
explained by either a decrease ofEC adherence before 
graft implantation or a decrease in the proliferative 
rate of the transduced ECs on the graft surfaces. The 
reported ecrease percent endothelialization may be 
partly explained by the impaired ability of the 
tPA-transduced ECs to adhere to the graft surface in 
vivo and suggests hat the tPA retroviral transduction 
may alter the biologie function of the EC. This 
observation merits further investigation. 
We ackälowledge Amy Kaddell for her technical 
assistance, Merlis Judge-Nolan for her combined adminis- 
trative and secretarial ssistance, and W. L. Gore & 
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